High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin

January 2013
Gastroenterology & Hepatology;Jan2013 Supplement, p16
Academic Journal
The article presents a study on the introduction of oral agents which can effectively cure hepatitis C virus (HCV) infection. It says that direct-acting antiviral agents that can be taken orally includes the NS5A replication complex inhibitor declatasvir and the nucleotide analogue NS5B inhibitor sofosbuvir. It mentions that the study was participated by HCV-infected patients. It adds that the treatment was well tolerated with low hemoglobin levels seen in ribavirin-treated patients.


Related Articles

  • Sofosbuvir and Ledipasvir combo Therapy for HCV: End game for interferon? Watkins, Richard R. // Infectious Disease Alert;Apr2014, Vol. 33 Issue 7, p73 

    The article discusses a study by E. Lawitz and colleagues on the efficacy of a fixed-dose combination tablet of sofosbuir and ledipasvir with and without ribavirn, for 8 weeks and 12 weeks in both treatment-naì and protease inhibitor treated patients who did not achieve sustained virological...

  • THE NEXT WAVE OF HCV CARE: ALL-ORAL TREATMENT STRATEGIES. Sulkowski, Mark // Johns Hopkins Advanced Studies in Medicine;Jun2014, Vol. 14 Issue 1, p16 

    Recently approved direct-acting antiviral agents (DAAs) are recommended for use in combination with peginterferon (PEG) for interferon (IFN)-eligible patients. PEG is associated with significant adverse events, and many patients are not eligible for PEG therapy due to comorbid conditions or...

  • The role of triple therapy for patients with HCV genotype 1. Lisker-Melman, Mauricio // Hot Topics in Viral Hepatitis;2011, Vol. 7 Issue 22, p7 

    The present standard of care (SOC) therapy of chronic hepatitis C virus (HCV) infections is pegylated interferon-alpha in combination with ribavirin (RBV). In HCV genotype 1 (G1) infections, undetectable HCV RNA in serum is achieved in 40% to 60% of patients after 48 weeks of treatment. Recently...

  • A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates.  // Gastroenterology & Hepatology;Jan2013 Supplement, p11 

    The article presents a study on the administration of ritonavir-boosted human immune virus (HIV) protease inhibitors among healthy volunteers. It states that the study has three clinical trials including the phase II hepatitis C virus (HCV)/(HIV) co infection study, the phase III sprint-2 study,...

  • ABSTRACT SUMMARY.  // Gastroenterology & Hepatology;Jan2013 Supplement, p10 

    The article presents abstracts on medical topics which include a clinical decision tool to predict sustained virologic response (SVR) and treatment response in patients treated with ribavirin and boceprever plus peginterferon, a comparison of twice-daily administration of telaprevir versus every...

  • Ledipasvir/Sofosbuvir Plus Ribavirin Effective for Hepatitis C Virus in Patients With Advanced Liver Disease. Schuyler, Devon // Gastroenterology & Hepatology;Nov2015, Vol. 11 Issue 11, p728 

    No abstract available.

  • Ledipasvir combination effective in treating HCV genotype 1.  // Infectious Disease News;Apr2013, Vol. 26 Issue 4, p18 

    The article discusses the ELECTRON study conducted by Dr. Edward Gane and colleagues which found that combined sofosbuvir, ledipasvir and ribavirin therapy is effective in treating patients with hepatitis C virus genotype 1.

  • Mericitabine improved outcomes from peginterferon/ribavirin therapy for chronic HCV.  // Infectious Disease News;Apr2013, Vol. 26 Issue 4, p29 

    The article discusses a clinical trial conducted by Dr. Paul J. Pockros and colleagues which found that the addition of mericitabine, a nucleoside polymerase inhibitor, to a pegylated interferon and ribavirin regimen can improve the outcomes of patients with chronic hepatitis C virus (HCV).

  • Sofosbuvir combination efficacious in difficult-to-treat HCV patients.  // Infectious Disease News;Apr2013, Vol. 26 Issue 4, p12 

    The article discusses a study conducted by Dr. Anu Osinusi and colleagues which found that combined sofosbuvir and ribavirin therapy is effective in treating patients with hepatitis C.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics